Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study

Table 3 Variance in preoperative clinicopathological parameters between patients with and without positive surgical margin (PSM)

	PSM present (n = 39)	PSM absent (n = 81)	Uniivariate	Multivariate
	PSM present (n = 39)	PSM absent (n = 81)	p-value	P value	Adjusted odds ratio (95% CI)
Mean age [years]	63.5 ± 36.0	64.0 ± 4.6	0.993
PSA [ng/ml]	9.8 ± 6.3	8.7 ± 7.8	0.247
Gleason score at biopsy	7.2 ± 1.2	7.0 ± 1.0	0.209
cT stage (n)			0.347
T1c	30 (76.9%)	65 (80.2%)
T2	5 (12.8%)	13 (16.0%)
T3a	4 (10.3%)	3 (3.7%)
%positive cores	31.0 ± 21.3	21.3 ±16.4	0.001	0.001	1.044 (1.019-1.070)
TZ biopsy positive (n)	17 (43.6%)	24 (29.6%)	0.131
Number of apex-positive (2–4/0–1) (n)	14/25	15/66	0.037
Number of middle-positive (2–4/0–1) (n)	17/22	15/66	0.004
Number of base-positive (2–4/0–1) (n)	13/26	14/67	0.049

PSA, prostate-specific antigen; TZ, transition zone; apex, prostatic apex biopsy; middle, prostatic middle biopsy; base, prostatic base biopsy. Data not available in 4 patients.

ISSN: 1746-1596